

35

# PATENT SPECIFICATION

NO DRAWINGS

860.708



Date of Application and filing Complete Specification: June 16, 1959.

No. 20590/59.

Application made in United States of America on June 23, 1958.

Complete Specification Published: Feb. 8, 1961.

Index at acceptance:—Class 81(1), B2(D:L:N:S:Z), B(3:4).

International Classification:—A61k.

## COMPLETE SPECIFICATION

### Medicinal Tablets Comprising 4-Aminoquinoline-Type Drugs and Salicylates

We, STERLING DRUG INC., a corporation organised under the laws of the State of Delaware, United States of America, of 1450, Broadway, New York, State of New York, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to medicinal compositions and to their preparation. These compositions are useful as antirheumatic agents, for instance, as anti-inflammatory agents for the treatment of rheumatoid arthritis.

In recent years a number of workers in search of drugs for treatment of rheumatic diseases have reported that 4-aminoquinoline-type antimalarial drugs, e.g., 7-chloro-4-(4-diethylamino-1-methylbutylamino)-quinoline diphosphate (chloroquine phosphate) and 7-chloro-4-[4-(N-ethyl-N-2-hydroxyethylamino)-1-methylbutylamino]-quinoline sulfate (hydroxychloroquine sulfate), are effective for this purpose.

However, the 4-aminoquinoline-type antimalarial drugs, when administered as antirheumatic agents have a very slow onset of action, and several months may elapse after medication has begun before any improvement can be perceived. During this period the co-administration of a salicylate gives the patient especially beneficial results because of the action of the salicylate in providing relief of pain, diminution of the inflammatory process, and stimulation of the adrenal cortex.

In search for an improved antirheumatic remedy in unit dosage form containing as essential ingredients both a 4-aminoquinoline-type antimalarial drug and a salicylate, e.g., containing chloroquine phosphate and aspirin or hydroxychloroquine sulfate and aspirin, we first prepared conventional tablets containing said ingredients but found these tablets to be unsatisfactory in having a

[Price 3s. 6d.]

bitter taste, poor disintegration properties and poor stability, as evidenced by discoloration and salicylic acid crystal formation on storage.

We have now found that a stable antirheumatic composition can be obtained by formulating a tablet containing a dry-compressed core comprising a 4-aminoquinoline-type antimalarial drug and adjuvants, and a dry-compressed shell coating comprising a salicylate and adjuvants, said tablet on storage retaining its original rapid disintegration properties, aspirin content and physical appearance, i.e., no discoloration or crystal formation. Further, these tablets did not have the objectionable bitter taste possessed by the above-described conventional tablet which contained the same essential ingredients.

By a 4-aminoquinoline-type antimalarial drug we mean both 4-aminoquinoline-type drugs in free base form and their acid-addition salts. These 4-aminoquinoline-type antimalarial drugs were studied extensively during and after World War II and are well-known in the art, e.g., see the Andersag et al. U.S. Patent 2,233,970 and Wiselogle's "Survey of Antimalarial Drugs 1941-1945," Volumes I-III, J. W. Edwards, Ann Arbor, Michigan, 1946. Preferred embodiments of the 4-aminoquinoline-type antimalarial drugs as used herein are acid-addition salts of chloroquine and hydroxychloroquine, e.g., chloroquine phosphate, hydroxychloroquine sulphate.

By a salicylate we mean a derivative of salicylic acid well-known to have analgesic and/or antirheumatic properties, e.g., acetylsalicylic acid (aspirin), ethyl salicylate, salicylamide, sodium salicylate and ammonium salicylate, the preferred embodiments being aspirin.

By adjuvants we mean excipients necessary for imparting satisfactory properties to the tablet, said excipients including: diluents, e.g., lactose, calcium carbonate, dibasic calcium phosphate ( $\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$ ), mag-

nesium carbonate, kaolin; disintegrators, e.g., starch; lubricants, e.g., talcum, magnesium stearate, stearic acid; and, alternatively, flavours, e.g., a fruit flavour, vanilla, chocolate, licorice. Preferred adjuvants used in formulating the core of our tablet were lactose and dibasic calcium phosphate as diluents, starch as the disintegrator, and talcum and magnesium stearate or stearic acid as lubricants. Preferred adjuvants used in formulating the shell coating around the core were starch, lactose and dibasic calcium phosphate.

Another aspect of our invention is the process for the preparation of the above-described stable medicinal composition in tablet form which comprises the steps of dry-compressing in granular form a 4-aminoquinoline - type antimalarial drug and adjuvants and then dry-compressing in granular form around the resulting core tablet a shell coating comprising a salicylate and adjuvants. Important features of the process are: the formation of the core and the final tablet by dry compression, thereby obviating the use of an aqueous or aqueous-alcohol medium; and, the use of the core and shell ingredients in granular form. Avoidance of water is desirable to prevent decomposition of aspirin or other salicylates. Use of the ingredients in granular form, e.g., about 12-50 mesh resulted in highly satisfactory tablets. (The mesh sizes referred to herein are in accordance with the specifications of the American Society for Testing Materials).

We obtained best results in our process using the same granular diluent in preparing the core and the shell coating. A particularly preferred diluent contained lactose and dibasic calcium phosphate with a small quantity of starch. In practice, we found especially suitable a granular diluent of approximately No. 16 mesh size and containing approximately 49% (by weight) each of lactose and dibasic calcium phosphate and approximately 2% (by weight) of starch. Such a granular diluent has the advantages of carrying with it other ingredients in flowing from the hopper into the dies of a tablet machine and in having an excellent compressible nature. Because of the latter property, its use in our process affords a strong bond between the core tablet and the shell coating, thereby lessening the chance of tablet splitting, which is a major problem in the formation of press-coated tablets.

The dosage quantities can be varied, using the principle of the invention herein described, to meet the needs of patients as determined by the prescribing physician. The following description is illustrative of the several varia-

tions within the range of unit dosages generally found desirable. For a tablet weighing about 0.5 gram, a quantity of a 4-aminoquinoline-type antimalarial drug in salt form weighing in the range of about 0.02 to 0.10 gram and a quantity of salicylate, e.g., aspirin, weighing in the range of about 0.15 to 0.30 gram were found satisfactory.

In addition to the essential ingredients of the tablets of this invention, other medicaments can be incorporated therein, preferably in the core. Such other medicaments are preferably those having antirheumatic and/or sedative properties, including corticosteroids, e.g., prednisone and cortisone; muscle relaxing agents, e.g., mephenesin and 2-(4-chlorophenyl) - 3 - methyl - 4 - metathiazanone-1-dioxide.

The following examples will further illustrate the invention without, however, limiting it thereto.

#### EXAMPLE 1.

The preparation of a granular diluent comprising lactose, dibasic calcium phosphate and a small quantity of starch is illustrated by the following granulation containing 49% (by weight) each of lactose and dibasic calcium phosphate and 2% (by weight) of starch: The lactose (USP) and dibasic calcium phosphate (USP) are mixed well to obtain uniform dispersion of the powders. A starch paste in distilled water (10% by weight of starch) was prepared by warming with stirring the starch (USP) and water. The starch paste was added to the powdered mixture of lactose and dibasic calcium phosphate; and the resulting mixture was mixed well with sufficient distilled water to obtain damp, powder-free granules. The wet material was passed through a No. 8 mesh screen and dried at about 50-55° C. The dried material was then passed through a No. 16 mesh screen. The resulting granular diluent was used in the following examples and as used therein will be designated "diluent granulation No. 16 mesh."

#### EXAMPLE 2.

This example illustrates a tablet weighing about 0.5 g. and containing a dry-compressed core comprising about 0.05 g. of a 4-aminoquinoline - type antimalarial drug and adjuvants, and a dry-compressed shell coating comprising about 0.3 g. of a salicylate and adjuvants. Thus, tablets each containing 0.050 g. of chloroquine phosphate in the core and 0.300 g. of aspirin in the shell coating were prepared as follows:

The core was prepared using the following ingredients:

Ingredient	Parts by Weight
Chloroquine phosphate (96.93%)	258
Diluent granulation No. 16 mesh	216
Starch	60
Talcum	60
Magnesium stearate	6

- After the chloroquine phosphate had been passed through a No. 20 mesh screen, the above ingredients, except the magnesium stearate, were mixed well. The mixture was then dry slugged and the slugs were ground and screened to No. 16 mesh granules. The magnesium stearate was added to the granules; and the resulting mixture was mixed well and dry-compressed with a one-fourth inch regular concave punch and die. The resulting individual cores had a thickness of about 0.136 inch, a hardness of about 3 Kg./cm.<sup>2</sup> (using a Strong Cobb Co. Tablet Hardness Tester) and a disintegration time of about 6—7 minutes. 15
- The shell coating was prepared from the following ingredients:

Ingredient	Parts by Weight
Aspirin-starch (90—10%) granulation	1665
Diluent granulation No. 16 mesh	235

- 20 The above ingredients in the form of No. 16 mesh granules were mixed well; and the resulting mixture was dry-compressed around the core tablets using a seven/sixteenths inch regular concave punch and die. The resulting tablets had a thickness of about 0.187 inch, a hardness of about 9 Kg./cm.<sup>2</sup> and assayed per tablet as follows: 25

Chloroquine phosphate	0.0498 gram
Aspirin	0.298 gram
Free salicylic acid	0.07%
Moisture	1.48%
Average weight	0.503 gram
Disintegration time*	5 to 8 minutes

\* Disintegration times listed here and elsewhere in the specification were determined according to a standard method described on page 936 of the "Pharmacopeia of the United States", Fifteenth Revision, 1955.

The tablets were then packaged in amber glass bottles and stored at 35° C. Subsequent assays are given as follows:

	1 month	3 months	6 months	8 months
Chloroquine phosphate (grams)	0.0503	—	—	0.0510
Free salicylic acid	0.09%	0.12%	0.11%	0.24%
Average weight (grams)	0.5000	0.4969	—	0.4984
Disintegration time (minutes)	7—9	7—8	8—10	8—9

- 5 Conventional tablets each weighing about 0.45 g. and containing about 0.025 g. of chloroquine phosphate and about 0.30 g. of aspirin were prepared using the following ingredients:

Ingredient	Parts by Weight
Chloroquine phosphate (96.93%)	25.8
Aspirin No. 20 mesh	300.0
Starch	45.0
Talcum	45.0
Diluent granulation No. 16 mesh	34.2

- 10 All of the above ingredients were mixed and passed through a No. 3 mesh screen; mixed well and dry-slugged; reduced to a No. 12 mesh granules; and dry-compressed with a seven/sixteenths regular concave punch and die. The resulting tablets had a bitter taste, a thickness of about 0.165—0.168 inch, a hardness of about 8—9 Kg./cm.<sup>2</sup> and assayed per tablet as follows: 15

Chloroquine phosphate	0.0235 gram
Aspirin	0.304 gram
Free salicylic acid	0.098%
Moisture	1.24%
Average weight	0.4489 gram
Disintegration time	1.5—3 minutes

- 20 After these tablets had been stored in amber glass bottles for three months at 35° C., they were grey in colour, had an odour of acetic acid and contained needle-like crystals, indicating breakdown of the aspirin to form acetic acid and free salicylic acid crystals. 25

## EXAMPLE 3.

5      Tablets each weighing about 0.5 g. and containing a dry-compressed core comprising about 0.06 g. of hydroxychloroquine sulphate and a dry-compressed shell coating compris-

ing about 0.3 g. of aspirin were prepared as follows:

The core was prepared using the following ingredients:

	Ingredient	Parts by Weight
	Hydroxychloroquine sulfate (98.2%)	305.5
10	Diluent granulation No. 16 mesh	78.5
	Starch	150.0
	Talcum	60.0
	Stearic Acid	6.0

15      After the hydroxychloroquine sulphate had been passed through a No. 20 mesh screen, all of the above ingredients except the stearic acid were mixed well. The mixture was then dry-slugged and the slugs were reduced to No. 16 mesh granules. The stearic acid was then added to the granules; and the resulting mixture was mixed well and dry-compressed with

a one-fourth inch regular concave punch and die. The resulting individual cores had a thickness of about 0.135 inch, a hardness of about 6 Kg./cm.<sup>2</sup> and a disintegration time of about 8 minutes. 20

The shell coating was prepared using the following ingredients: 25

Ingredient	Parts by Weight
Aspirin-starch (90—10%) granulation	1665
Diluent granulation No. 16 mesh	235

30      The above ingredients in the form of granules (No. 16 mesh) were mixed well; and the resulting mixture was dry-compressed around the core tablets using a seven-sixteenths inch

regular concave punch and die. The resulting tablets had a thickness of about 0.188 inch, a hardness of about 8—10 Kg./cm.<sup>2</sup> and assayed per tablet as follows:

	Hydroxychloroquine sulphate	0.0611 gram
	Aspirin	0.308 gram
	Free salicylic acid	0.071%
35	Moisture	1.42%
	Average weight	0.4942 gram
	Disintegration time	7—8 minutes

The tablets were then packaged in amber glass bottles and stored at 35° C. Subsequent assays are given as follows:

	1 month	3 months	6 months
Hydroxychloroquine sulphate (grams)	0.0615	—	—
Aspirin (grams)	0.293	—	—
Free salicylic acid	0.11%	0.144%	0.16%
Average weight (grams)	—	0.4951	0.4953
Disintegration time (minutes)	10—12	10—11	11—13

- 5 Satisfactory tablets were also formulated according to the above procedure using magnesium stearate in place of stearic acid. Conventional tablets each weighing about 0.45 g. and containing about 0.030 g. of hydroxychloroquine sulfate and about 0.30 g. of aspirin were prepared using the following ingredients: 10

Ingredient	Parts by Weight
Hydroxychloroquine sulphate (98.2%)	30.55
Aspirin No. 80 mesh	300.00
Starch	45.00
Talcum	45.00
Diluent granulation No. 16 mesh	29.45

- 15 The above ingredients were mixed and passed through a No. 30 mesh screen; mixed well and dry slugged; reduced to No. 12 mesh granules; and compressed with a regular concave punch and die. The resulting tablets had a bitter taste, a thickness of about 0.185—0.190 inch, a hardness of about 7—8 Kg./cm.<sup>2</sup> and assayed per tablet as follows: 20

Hydroxychloroquine sulphate	0.032 gram
Aspirin	0.305 gram
Free salicylic acid	0.072%
Moisture	0.66%
Average weight	0.4473 gram
Disintegration time	54—96 minutes

- 25 After these tablets had been stored in amber glass bottles for three months at 35° C., they had a greyish appearance, an odour of acetic acid, a hardness of 12—14 Kg. and a free salicylic acid content of 0.435%.

#### EXAMPLE 4.

Tablets were made according to the procedure described in Example 2 having the following ingredients per tablet: 30

Ingredient	Weight, grams Per Tablet
<u>Core:</u>	
Chloroquine phosphate (96.93%)	0.0258
Diluent granulation No. 16 mesh	0.0690
Starch	0.0120
Talcum	0.0120
Magnesium stearate	0.0012
<u>Shell:</u>	
Aspirin-starch (90—10%) granulation	0.3330
Diluent granulation No. 16 mesh	0.0970

## Assay Data

	Original	3 Months at 35° C.
Average tablet weight (grams)	0.548	—
Chloroquine phosphate (grams)	0.0235	—
Aspirin (grams)	0.290	—
Free salicylic acid	0.092%	0.13%
Disintegration (minutes)	3—25	9—13
Moisture	1.3%	—

EXAMPLE 5. procedure described in Example 3 having the  
Tablets were prepared according to the following ingredients per tablet:

5

Ingredient	Weight, grams Per Tablet
<u>Core:</u>	
Hydroxychloroquine sulphate (98.95%) <sup>⊙</sup>	0.0303
Diluent granulation No. 16 mesh	0.0465
Starch	0.0300
Talcum	0.0120
Magnesium stearate	0.0012

Shell:

Aspirin-starch (90—10%) granulation	0.3330
Diluent granulation No. 16 mesh	0.0970

Assay Data

	Original	3 Months at 35° C.
Average tablet weight (grams)	0.5480	0.5481
Hydroxychloroquine sulphate (grams)	0.0291	—
Aspirin (grams)	0.304	—
Free salicylic acid	0.115%	0.12%
Disintegration (minutes)	5—12	6—9

WHAT WE CLAIM IS:—

5 1. A stable medicinal composition in tablet form composed of a dry-compressed core comprising a 4-aminoquinoline-type antimalarial drug and adjuvants, and a dry-compressed shell coating comprising a salicylate and adjuvants.

10 2. A stable medicinal composition according to claim 1, in which the antimalarial drug is an acid-addition salt of chloroquine.

3. A stable medicinal composition according to claim 2, in which the salt is chloroquine phosphate.

15 4. A stable medicinal composition according to claim 1, in which the antimalarial drug is an acid-addition salt of hydroxychloroquine.

20 5. A stable medicinal composition according to claim 4, in which the salt is hydroxychloroquine sulphate.

25 6. A stable medicinal composition according to any one of the preceding claims, in which the adjuvants for the antimalarial drug comprise a diluent, disintegrator and lubricant and the adjuvants for the salicylate comprise a disintegrator and diluent.

7. A stable medicinal composition according to any one of the preceding claims, in

which the adjuvant for the antimalarial drug and/or the salicylate comprises lactose, starch and dibasic calcium phosphate and the salicylate is aspirin. 30

8. A process for the preparation of the stable medicinal composition in tablet form according to any one of the preceding claims, which comprises dry-compressing in granular form the 4-aminoquinoline-type antimalarial drug and adjuvants and dry-compressing in granular form around the resulting core tablet a shell coating comprising the salicylate and adjuvants. 35 40

9. A process for the preparation of the stable medicinal composition according to claim 1 in tablet form substantially as herein described with reference to the Examples. 45

10. A stable medicinal composition prepared by the process according to claim 8 or 9.

11. A stable medicinal composition according to claim 1 substantially as herein described with reference to the Examples. 50

STEVENS, LANGNER, PARRY &  
ROLLINSON,  
Chartered Patent Agents,  
Agents for the Applicants.